No information is available on the clinical use of pralsetinib during breastfeeding. Because pralsetinib is 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 22 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during pralsetinib therapy and for 1 week after the last dose.
关于普拉替尼在母乳喂养期间的临床应用尚无可用信息。由于普拉替尼与血浆蛋白的结合率为97%，其在乳汁中的含量可能较低。然而，其半衰期约为22小时，可能会在婴儿体内蓄积。制造商建议在普拉替尼治疗期间及最后一剂后1周内停止母乳喂养。
